BIT225 in Phase II Trial for HIV and Hep C Co-Infection
November 15, 2012
Biotron begins key human trial of HIV/HCV drug
Friday, November 09, 2012 by Angela Kean
Biotron (ASX: BIT) has begun a landmark phase two human trial of its lead antiviral drug candidate, BIT225, in patients that are co-infected with both HIV and the Hepatitis C virus (HCV).
Twelve HIV/HCV-positive patients will receive 28 days treatment with BIT225 – 300 milligrams, twice daily – in combination with the standard approved treatment, interferon and ribavirin, for HCV.
The trial, which is being conducted at the Siriraj Hospital in Bangkok, is currently recruiting patients and is expected to be completed in the first half of 2013.
Continue reading this entire article:
Hepatitis B Virus Destroyed by Inovio's Vaccine
Trial Enrollment Begins for Abbott's Hep C Trio